AXGN CEO Dale Michael D sold 25,000 shares at $30.00, reducing holdings by 28.2% amid 85.2% 90-day gain.
CEO Dale Michael D sold 25,000 shares (25.0K shares) at $30.00, reducing his holding from 88,537 to 63,537 shares—a -28.2% reduction in the CEO's disclosed position. The sale occurs after a substantial 90-day run (+85.2%) and within 8.8% of the 52-week high ($33.32), consistent with selling into strength. The company is growing revenue at +17.8% annually and posted $60.1M in the latest quarter, though it remains unprofitable on a full-year basis with $708.0K net income (latest quarter) against negative full-year net income. This is the CEO's only prior sale on record, so there is no established timing pattern to assess; the transaction timing relative to peak valuations warrants investor attention given the sustained price momentum and the company's profitability challenges.
CEO Dale Michael D sold 61,463 shares of AXGN at $31.21, reducing stake by 41.0% to 88,537 shares post-transaction.
CEO Dale Michael D executed a substantial open-market sale of 61,463 shares at $31.21, representing a 41.0% reduction in his holdings from 150,000 shares to 88,537 shares. The sale occurred near the company's 52-week high of $33.32 (current price $30.01 is 9.9% below that peak), and follows a strong 30-day (+25.0%) and 90-day (+78.6%) price appreciation. While Axogen shows solid revenue growth of +17.8% year-over-year and generated $708,000 in net income in the latest quarter, the company remains unprofitable on a full-year basis. The magnitude of this reduction—eliminating 41.0% of his stake in a single transaction—reflects a material reallocation of his personal wealth exposure to the company at a point when the stock price has recovered substantially from its 52-week low of $9.29.
